The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer

Figures & data

Figure 1 Panitumumab, a fully humanized monoclonal IgG2 antibody, inhibits the EGFR pathway.

Abbreviations: AKT, AKT8 virus oncogene cellular homolog; EGFR, epidermal growth factor receptor; ERK, extracellular signal–regulated kinase; MEK, mitogen-activated protein kinase kinase; mTOR, mammalian target of rapamycin; PI3K, phosphatidyilinositol 3-kinase; PTEN, phosphatase and tensin homolog; RAF, v-Raf murine sarcoma viral oncogene homolog; RAS, rat sarcoma viral oncogene homolog.

Table 1 Efficacy results from main panitumumab trials

Trial (phase) Ref	Treatment Arms (n.)	Treatment Line	Primary Endpoint	ORR (%)		PFS		OS
KRAS ex 2 WT	RAS WT	KRAS ex 2 WT	RAS WT	KRAS ex 2 WT	RAS WT
408 (III) NCT00113763 ^Citation10^,^Citation11^,^Citation20	Panitumumab (n.231) BSC (n.232)	3rd/+	PFS	17% 0%	17% 0%	2.87 m (n.124) 1.7 m (n.119) [HR 0.45; P<0.0001]	HR 0.39; 95% CI, 0.27–0.56; P<0.001	8.1 m (n.124) 7.6 m (n.119) [HR 0.99; 95% CI, 0.75–1.29]	Not reported
0007 (III) NCT01412957 ^Citation80	Panitumumab (n.189) BSC (n.188)	3rd/+	OS	27% 1.6% [P<0.0001]	31% 2.3% [P<0.0001]	3.6 m (n.189) 1.7 m (n.188) [HR 0.51; P<0.0001]	5.2 m (n.142) 1.7 m (n.128) [HR 0.46; P<0.0001]	10 m (n.189) 7.4 m (n.188) [HR 0.73; P=0.0096]	10 m (n.142) 6.9 m (n.128) [HR 0.70; P=0.0135]
ASPECCT (III) NCT01001377 ^Citation12	Panitumumab (n.499) Cetuximab (n.500)	3rd/+	OS	22% 20%	NE	4.1 m (n.499) 4.4 m (n.500) [HR 1.00; 95% CI, 0.88–1.14]	NE	10.4 m (n.499) 10 m (n.500) [HR 0.97; Z-score −3.19; P=0.0007]	NE
PRIME (III) NCT00364013 ^Citation15^,^Citation16	FOLFOX + Panitumumab (n.593) FOLFOX (n.590)	1st	PFS	57% 48% [P=0.02]	Not reported	10.0 m (n.325) 8.6 m (n.331) [HR 0.80; P=0.01]	10.1 m (n.259) 7.9 m (n.253) [HR 0.72; P=0.004]	23.8 m (n.325) 19.4 m (n.331) [HR 0.83; P=0.03]	25.8 m (n.259) 20.2 m (n.253) [HR 0.77; P=0.009]
314 (II) NCT00508404 ^Citation19^,^Citation47	FOLFIRI + Panitumumab (n.154)	1st	ORR	56%	59%	8.9 m (n.86)	11.2 m (n.68)	Not Reported	Not reported
PEAK (II) NCT00819780 ^Citation25^,^Citation26	FOLFOX + Panitumumab (n.142) FOLFOX + Bevacizumab (n.143)	1st	PFS	57.8% 53.5%	65% 60%	10.9 m (n.142) 10.1 m (n.143) [HR 0.87; P=0.35]	12.8 m (n.88) 10.1 m (n.82) [HR 0.68; P=0.029]	34.2 m (n.142) 24.3 m (n.143) [HR 0.62; P=0.009]	36.9 m (n.88) 28.9 m (n.82) [HR 0.76; P=0.15]
PLANET-TTD (II) NCT00885885 ^Citation28	FOLFOX + Panitumumab (n.38) FOLFIRI + Panitumumab (n.39)	1st	ORR	74% 67%	78% 73%	13 m (n.38) 14 m (n.39) [HR 0.90; P=0.728]	13 m (n.27) 15 m (n.26) [HR 0.70; P=0.307]	37 m (n.38) 41 m (n.39) [HR 1.0; P=0.966]	39 m (n.27) 49 m (n.26) [HR 0.9; P=0.824]
VOLFI (II) NCT01328171 ^Citation35	mFOLFOXIRI + Panitumumab (n.63) mFOLFOXIRI (n.33)	1st	ORR	-	87.3% 60.6%; [P=0.0041]	-	9.7 m (n.63) 10.1 m (n.33) [HR 0.92; P=0.72]	Not Reported	Not Reported
181 (III) NCT00339183 ^Citation13,Citation14,Citation81	FOLFIRI + Panitumumab (n.591) FOLFIRI (n.595)	2nd	PFS, OS	35% 10% [P<0.0001]	41% 10%	5.9 m (n.303) 3.9 m (n.294) [HR 0.73; P=0.004]	6.4 m (n.208) 4.6 m (n.213) [HR 0.70; P=0.007]	14.5 m (n.303) 12.5 m (n.294) [HR 0.85; P=0.12]	16.2 m (n.303) 13.9 m (n.294) [HR 0.81; P=0.08]
SPIRITT (II) NCT00418938 ^Citation82	FOLFIRI + Panitumumab (n.91) FOLFIRI + Bevacizumab (n.91)	2nd	PFS	32% 19%	NE	7.7 m (n.91) 9.2 m (n.91) [HR 1.01; P=0.97]	NE	18 m (n.91) 21.4 m (n.91) [HR 1.06; P=0.75]	NE

Abbreviations: BSC, best supportive care; CI, confidence interval; ex, exon; HR, hazard ratio; m, months; n, number of patients; NE, not evaluated; PFS, progression free survival; ORR, objective response rate; OS, overall survival; Ref, reference; WT, wild-type.

Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25(13):1658–1664. doi:10.1200/JCO.2006.08.162017470858

 PubMed Web of Science ®Google Scholar

Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(10):1626–1634. doi:10.1200/JCO.2007.14.711618316791

 PubMed Web of Science ®Google Scholar

Peeters M, Oliner KS, Parker A, et al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res. 2013;19(7):1902–1912. doi:10.1158/1078-0432.CCR-12-191323325582

 PubMed Web of Science ®Google Scholar

Kim TW, Elme A, Kusic Z, et al. A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer. Br J Cancer. 2016;115(10):1206–1214. doi:10.1038/bjc.2016.30927736842

 PubMed Web of Science ®Google Scholar

Price TJ, Peeters M, Kim TW, et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol. 2014;15(6):569–579. doi:10.1016/S1470-2045(14)70118-424739896

 PubMed Web of Science ®Google Scholar

Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28(31):4697–4705. doi:10.1200/JCO.2009.27.486020921465

 PubMed Web of Science ®Google Scholar

Douillard JY, Siena S, Cassidy J, et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol. 2014;25(7):1346–1355. doi:10.1093/annonc/mdu14124718886

 PubMed Web of Science ®Google Scholar

Karthaus M, Hofheinz RD, Mineur L, et al. Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer. Br J Cancer. 2016;115(10):1215–1222. doi:10.1038/bjc.2016.34327764839

 PubMed Web of Science ®Google Scholar

Kohne CH, Hofheinz R, Mineur L, et al. First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol. 2012;138(1):65–72. doi:10.1007/s00432-011-1061-621960318

 PubMed Web of Science ®Google Scholar

Schwartzberg LS, Rivera F, Karthaus M, et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol. 2014;32(21):2240–2247. doi:10.1200/JCO.2013.53.247324687833

 PubMed Web of Science ®Google Scholar

Rivera F, Karthaus M, Hecht JR, et al. Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma. Int J Colorectal Dis. 2017;32(8):1179–1190. doi:10.1007/s00384-017-2800-128424871

 PubMed Web of Science ®Google Scholar

Carrato A, Abad A, Massuti B, et al. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: a randomised, phase II trial (PLANET-TTD). Eur J Cancer. 2017;81:191–202. doi:10.1016/j.ejca.2017.04.02428633089

 PubMed Web of Science ®Google Scholar

Geissler M, Klingler T, Martens UM, et al. 453PD1st-line mFOLFOXIRI + panitumumab vs FOLFOXIRI treatment of RAS wt mCRC: a randomized phase II VOLFI trial of the AIO (KRK-0109). Ann Oncol. 2018;29(suppl_8). doi:10.1093/annonc/mdx807

 Google Scholar

Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28(31):4706–4713. doi:10.1200/JCO.2009.27.605520921462

 PubMed Web of Science ®Google Scholar

Peeters M, Oliner KS, Price TJ, et al. Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer. Clin Cancer Res. 2015;21(24):5469–5479. doi:10.1158/1078-0432.CCR-15-052626341920

 PubMed Web of Science ®Google Scholar

Peeters M, Price TJ, Cervantes A, et al. Final results from a randomized phase 3 study of FOLFIRI {±} panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol. 2014;25(1):107–116. doi:10.1093/annonc/mdt52324356622

 PubMed Web of Science ®Google Scholar

Hecht JR, Cohn A, Dakhil S, et al. SPIRITT: a randomized, multicenter, phase II study of panitumumab with FOLFIRI and bevacizumab with FOLFIRI as second-line treatment in patients with unresectable wild type KRAS metastatic colorectal cancer. Clin Colorectal Cancer. 2015;14(2):72–80. doi:10.1016/j.clcc.2014.12.00925982297

 PubMed Web of Science ®Google Scholar